Chemical structure of anisomycin.
Western blot analysis of extracts from 293T cells, treated with Anisomycin (25 μg/ml) for the indicated times, with or without pretreatment with JNK inhibitor SP600125 (50 μM, 40 min; +), using Phospho-JunB (Thr102/Thr104) (D3C6) Rabbit mAb #8053 (upper) or JunB (C37F9) Rabbit mAb #3753 (lower).
Western blot analysis of extracts from Jurkat cells, serum-starved overnight, pretreated with the indicated concentrations of SB202190 for 1 hr, and subsequently treated with Anisomycin (25 μg/ml, 30 min; +), using Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb #4511 (upper) or p38 MAPK Antibody #9212 (lower).
Anisomycin is supplied as a lyophilized powder. For a 25 mg/ml stock, reconstitute the 10 mg in 400 µl DMSO. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 5-50 µg/ml for 5-60 minutes. Soluble in DMSO or MeOH.
Store lyophilized or in solution at 4ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|Molecular Weight||265.3 g/mol|
|Solubility||Soluble in DMSO at 100mg/ml and MeOH at 50mg/ml.|
Anisomycin, an antibiotic produced by Streptomyces griseolus and S. roseochromogenes, was originally described to inhibit protein-protein synthesis at the translational level (1). More recently, it is has been well characterized to strongly activate the stress kinases SAPK/JNK and p38 MAPK, as well as p70/85 S6 kinase in mammalian cells, which results in the rapid induction of immediate-early (IE) genes, such as c-fos, fosB, c-jun, JunB, and JunD (1). Investigators have demonstrated that anisomycin acts as a potent signaling agonist, synergizing with growth factors and phorbol esters to superinduce these IE genes (1,2). Research studies have demonstrated that anisomycin induces apoptosis in many cancer cell lines (3-5).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.